Matinas BioPharma Holdings, Inc. Share Price
AMEX: MTNB | Micro CapMatinas BioPharma Holdings, Inc. Stock Performance
Open $0.26 | Prev. Close $0.26 | Circuit Range N/A |
Day Range $0.26 - $0.27 | Year Range $0.23 - $2.20 | Volume 1,775 |
Average Traded $0.27 |
Matinas BioPharma Holdings, Inc. Share Price Today
As of 11 August 2026, Matinas BioPharma Holdings, Inc.'s share price is $0.27. The stock opened at $0.26, compared to its previous close of $0.26. During today's trading session, Matinas BioPharma Holdings, Inc.'s share price traded between $0.26 and $0.27, with an average price of $0.27. Over the past 52 weeks, the stock has recorded a high of $2.20 and a low of $0.23. In terms of performance, Matinas BioPharma Holdings, Inc.'s share price has declined by 55.86% over the last six months and is down 85.46% on a year-on-year basis.
Matinas BioPharma Holdings, Inc. Share Price Chart
Matinas BioPharma Holdings, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.46M | PE Ratio (TTM) -0.13 | Dividend Yield N/A |
EPS (TTM) $-2.00 | Revenue (TTM) -$6.96M | Return On Equity (TTM) -214.18% |
Profit Margin 148.64% | Debt to Equity 0.30 | Quarterly Earnings Growth YoY 64.16% |
Matinas BioPharma Holdings, Inc. Quarterly Profit & Loss
All figures in USD
Matinas BioPharma Holdings, Inc. Annual Profit & Loss
All figures in USD
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Matinas BioPharma Holdings, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.28 | $0.27 | -7.93% |
Jul 2026 | $0.63 | $0.29 | -55.45% |
Jun 2026 | $0.81 | $0.65 | -17.59% |
May 2026 | $0.67 | $0.79 | +19.70% |
Apr 2026 | $0.53 | $0.66 | +32.00% |
Mar 2026 | $0.61 | $0.50 | -17.49% |
Feb 2026 | $0.59 | $0.61 | +1.34% |
Jan 2026 | $0.59 | $0.60 | +3.10% |
Dec 2025 | $0.72 | $0.58 | -24.77% |
Nov 2025 | $1.32 | $0.77 | -45.32% |
Oct 2025 | $1.89 | $1.41 | -26.94% |
Sep 2025 | $1.73 | $1.93 | +4.89% |
MTNB Share Price FAQs
What is Matinas BioPharma Holdings, Inc. share price today?
What is the 52 week high and 52 week low of Matinas BioPharma Holdings, Inc. stock?
What is MTNB's market capitalisation today?
What is MTNB's net income for the last quarter?
What is the 5 year returns of MTNB?
What is the high & low stock price of MTNB today?
Can I buy MTNB shares in India?